Virginia Retirement Systems ET AL purchased a new position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 5,600 shares of the company’s stock, valued at approximately $284,000.

Other institutional investors have also recently made changes to their positions in the company. Parallel Advisors LLC grew its holdings in Ionis Pharmaceuticals by 62.8% in the 2nd quarter. Parallel Advisors LLC now owns 2,073 shares of the company’s stock worth $109,000 after acquiring an additional 800 shares during the last quarter. Aviva PLC purchased a new stake in shares of Ionis Pharmaceuticals in the 2nd quarter worth about $10,187,000. Allen Investment Management LLC lifted its position in shares of Ionis Pharmaceuticals by 64.7% in the 2nd quarter. Allen Investment Management LLC now owns 15,652 shares of the company’s stock worth $796,000 after purchasing an additional 6,147 shares during the period. Russell Investments Group Ltd. lifted its position in shares of Ionis Pharmaceuticals by 21.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 20,077 shares of the company’s stock worth $1,021,000 after purchasing an additional 3,538 shares during the period. Finally, Rothschild Asset Management Inc. lifted its position in shares of Ionis Pharmaceuticals by 10.8% in the 3rd quarter. Rothschild Asset Management Inc. now owns 281,068 shares of the company’s stock worth $14,250,000 after purchasing an additional 27,426 shares during the period. 91.57% of the stock is currently owned by institutional investors and hedge funds.

In related news, CEO Stanley T. Crooke sold 15,000 shares of Ionis Pharmaceuticals stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $52.00, for a total transaction of $780,000.00. Following the completion of the transaction, the chief executive officer now directly owns 43,014 shares of the company’s stock, valued at approximately $2,236,728. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Elizabeth L. Hougen sold 4,000 shares of Ionis Pharmaceuticals stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $57.00, for a total transaction of $228,000.00. Following the transaction, the senior vice president now directly owns 14,392 shares of the company’s stock, valued at $820,344. The disclosure for this sale can be found here. Over the last three months, insiders have sold 123,886 shares of company stock valued at $7,098,315. 2.13% of the stock is currently owned by corporate insiders.

Several equities research analysts have recently commented on IONS shares. Goldman Sachs Group reaffirmed a “sell” rating and issued a $30.00 target price on shares of Ionis Pharmaceuticals in a research report on Friday, October 6th. Zacks Investment Research raised shares of Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $62.00 target price for the company in a research report on Friday, October 27th. Needham & Company LLC reaffirmed a “buy” rating and issued a $64.00 target price on shares of Ionis Pharmaceuticals in a research report on Sunday, September 17th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $50.00 target price on shares of Ionis Pharmaceuticals in a research report on Friday, October 13th. Finally, Barclays started coverage on shares of Ionis Pharmaceuticals in a research report on Wednesday, September 6th. They issued an “equal weight” rating and a $55.00 target price for the company. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $50.31.

Ionis Pharmaceuticals, Inc. (NASDAQ IONS) opened at $53.57 on Thursday. Ionis Pharmaceuticals, Inc. has a 12-month low of $37.26 and a 12-month high of $65.51. The stock has a market cap of $6,657.84, a PE ratio of 355.67 and a beta of 2.85. The company has a debt-to-equity ratio of 1.50, a quick ratio of 6.21 and a current ratio of 6.25.

ILLEGAL ACTIVITY NOTICE: “Virginia Retirement Systems ET AL Invests $284,000 in Ionis Pharmaceuticals, Inc. (IONS) Stock” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/12/14/virginia-retirement-systems-et-al-invests-284000-in-ionis-pharmaceuticals-inc-ions-stock.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Stock Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related stocks with our FREE daily email newsletter.